P-21

P-21 (also designated P021) is a synthetic tetrapeptide (four amino acids: Ac-DGGLAG-NH2) derived from the biologically active region of human ciliary neurotrophic factor (CNTF). CNTF is a naturally occurring cytokine that supports neuronal survival and differentiation, but native CNTF is too large to cross the blood-brain barrier efficiently and produces systemic side effects at therapeutic doses. P-21 was engineered to retain the neurotrophic activity of CNTF's active domain while incorporating an adamantylated glycine residue at the C-terminal end. This adamantane modification serves two critical purposes: it increases the molecule's lipophilicity to improve blood-brain barrier penetration, and it protects against degradation by exopeptidases, extending the peptide's functional half-life in biological tissues.

The central mechanism of P-21 involves two complementary actions on neurotrophin signaling. First, P-21 inhibits leukemia inhibitory factor (LIF) signaling ^[1], which normally acts as a brake on adult neurogenesis. By suppressing LIF's inhibitory effect, P-21 removes a significant barrier to new neuron formation in the hippocampus, a region critical for learning, memory consolidation, and spatial navigation. Second, P-21 upregulates the expression of brain-derived neurotrophic factor (BDNF), activating the downstream BDNF/TrkB/PI3-K/AKT/GSK3-beta signaling cascade. BDNF is often described as a master regulator of neuroplasticity, promoting synaptic strengthening, dendritic branching, and neuronal survival throughout the adult brain.

Animal research has produced particularly compelling results in Alzheimer's disease models. In the triple-transgenic mouse model of Alzheimer's disease (3xTg-AD), P-21 treatment initiated at 9-10 months of age and continued for 6-12 months produced multiple disease-modifying effects: rescued deficits in hippocampal neurogenesis, restored synaptic density to near-normal levels ^[2], normalized BDNF expression and glutamate receptor levels, and reversed cognitive impairments across multiple memory tasks. Crucially, P-21 also inhibited the formation of amyloid-beta plaques and tau hyperphosphorylation, two of the hallmark pathological features of Alzheimer's disease, addressing disease biology rather than merely symptomatic expression.

P-21 is under active clinical development by Phanes Biotech (PA, USA) as a potential disease-modifying therapy for Alzheimer's disease and other neurodegenerative conditions. As of early 2026, no human clinical trial results have been published. The peptide is classified as a research compound and is not approved for any human therapeutic indication. Interest in P-21 has grown alongside broader interest in neurogenesis-promoting strategies as an alternative to amyloid clearance approaches that have shown variable results in late-stage clinical trials.